Trump Not Keen On Changing CMS’ Biosimilar Pay Policies, Sources Say

Changing CMS’ controversial policy of lumping biosimilars that reference the same biologic under a single same billing code is not a high priority for the Trump administration, two sources in touch with the White House said Tuesday (June 13). One source predicted that the administration won’t reexamine the existing policies until more biosimilars, and particularly interchangeables, come to market. However, one industry expert argued that companies likely won’t pursue developing interchangeable products -- those seen as offering the biggest potential...